U.S. Bill Proposes 12-Year Market Exclusivity for FDA-Approved Botanical Drugs

A bill introduced in the U.S. House of Representatives on August 27, 2026, would create a special 12-year market exclusivity period for certain FDA-approved botanical drugs. The Advancing Botanical Drug Development Act of 2026 (H.R. 10150), sponsored by Representative Lauren Boebert and co-sponsored by Representative Derrick Van Orden, seeks to encourage investment in a drug category that proponents describe as important and overlooked.

Under the proposed legislation, if a botanical drug is approved through the FDA's standard new drug application (NDA) process, the FDA could not allow a generic or other follow-on application referencing that drug to become effective for 12 years. The bill does not alter the safety or effectiveness standards for approval; botanical drugs would still need to meet the FDA's normal requirements.

Rationale for the Legislation

The bill states that botanical drugs can be harder and more expensive to develop than conventional drugs because plant-based ingredients can vary and require additional work to ensure consistent quality, safety, and effectiveness. It argues that existing patent and exclusivity protections may be insufficient to attract investment in this area, and that a longer exclusivity period could encourage more research and development of botanical treatments.

Representative Boebert emphasized the therapeutic potential of botanical drugs, stating that "because they contain many natural compounds, they can work on multiple targets at once, which may help with complex chronic and age-related conditions such as Alzheimer's (搜索)搜索该疾病, Parkinson's (搜索)搜索该疾病." She added that "the bill seeks to expand treatment options for complex chronic and age-related diseases while maintaining existing FDA safety and efficacy requirements."

Industry Response

Legacy Healthcare (搜索)搜索该词条, a Switzerland-based company, welcomed the introduction of the legislation. "Botanical drugs can indeed act on multiple biological targets at once, offering potential to unlock treatments for many unmet medical needs," said Saad Harti, founder and CEO of Legacy Healthcare. "A clear and appropriate period of post-approval market exclusivity will strengthen the ability to attract investment in this emerging drug category – much favored by patients."

Representative Boebert further noted that "the legislation would address barriers to late-stage development of botanical medicines by providing a defined period of regulatory exclusivity for qualifying products, thereby creating the certainty needed to support rigorous development of so promising multi-constituent therapies can reach patients."

Legacy Healthcare's Lead Candidate

Legacy Healthcare (搜索)搜索该词条's lead candidate, Cinainu (搜索)搜索该药品, is described as the first botanical drug for an autoimmune disease authorized to enter Phase 3 by the U.S. Food and Drug Administration and Japanese health authorities (PMDA). In a Phase 2/3 study in alopecia areata (搜索)搜索该疾病, Cinainu demonstrated efficacy, long-term effect, and no autoimmune-related side effects, which the company characterizes as a first. The company is currently raising financing to conduct the FDA- and PMDA-authorized Phase 3 program. If approved, Cinainu would be the first treatment for children, adolescents, and adults with both severe and moderate alopecia areata. Cinainu is supported by intellectual-property protection extending through 2043.

Practical Implications

For companies developing approved botanical drugs, the bill would provide a longer period of protection from direct FDA-approved competition, potentially giving those products more time on the market without generic or similar follow-on versions. For patients and health care providers, the primary effect would be on when lower-cost competing versions of those products could become available.